NS 9283

NS 9283 (A-969933) is a α4β2 nicotinic acetylcholine receptor (α4β2 nAChR) positive allosteric modulator that preferentially targets the (α4)₃ (β2)₂ stoichiometric conformation. NS 9283 increases the potency of ACh-induced currents without enhancing the maximal effect of ACh. NS 9283 also enhances prefrontal glutamate release, modulates attention-related electrophysiological responses, and potentiates the antinociceptive effects associated with α4β2 nAChR agonists. NS 9283 can be used in research related to inflammatory pain, postoperative pain, osteoarthritis pain, and Parkinson's disease^{[1][2][3][4][5][6][7]}.
In Vitro:NS 9283 (A-969933) (10 μM; HEK293-hα4β2 cells) shifts the acetylcholine concentration-response relationship leftward by approximately 60-fold, without significantly altering the maximal efficacy of ACh^[4].
NS 9283 (10 μM) moderately reduces the desensitization recovery rate of stably expressed human (α4)₃ (β2)₂ nAChR in HEK293 cells^[4].
NS 9283 (10 μM) significantly slows the deactivation kinetics of stably expressed human (α4)₃ (β2)₂ nAChR in HEK293 cells, increasing the deactivation time constant to 65 ms^[4].
NS 9283 (pre-incubated with ACh for approximately 40 s at a concentration of 10 μM prior to co-administration) enhances the inward current signal of human α4β2 nicotinic acetylcholine receptors expressed in HEK293 cells. In the experiment, a physiologically relevant concentration of 1 μM ACh is used, yielding an average peak current of 78 pA^[1].
NS 9283 (30 μM) does not enhance (-)-nicotine-induced dopamine release in rat striatal slices, indicating that functional striatal α4β2 nAChRs belong to the high-sensitivity subtype^[3]. In Vivo:NS 9283 (A-969933) (administered via intraperitoneal injection at doses of 0.075-7.5 mg/kg, 20 minutes prior to the start of testing) alone does not produce nicotine-like discriminative effects. When combined with a non-effective dose of nicotine (0.025 mg/kg), it dose-dependently increases nicotine-appropriate lever selection, and achieves full generalization at 7.5 mg/kg NS 9283^[7].
NS 9283 (0.3-3.0 mg/kg; p.o.; single administration) enhances the amplitude of P3-like event-related potentials (ERP) in the mediodorsal thalamic nucleus (MD) (0.3 mg/kg) and auditory cortex (AC) (3.0 mg/kg) of rats, increases the amplitude of the pre-attentive N1 peak in the mediodorsal thalamic nucleus (0.3 mg/kg), and prolongs the latency of P3-like event-related potentials in the medial prefrontal cortex (mPFC) (3.0 mg/kg), without improving overall task performance^[2].
NS 9283 (1-30 mg/kg; p.o.; single administration) alone has no effect on rotational behavior in 6-OHDA-lesioned rats, but co-administration with NS3956 (HY-183666) inhibits rotational behavior^[3].
NS 9283 (3-30 mg/kg; p.o.; single administration; 30 min before formalin injection) exerts no analgesic effect when used alone in the rat formalin pain model, but potentiates the antinociceptive effect of NS3956 by 100-fold across all test phases^[3].
Co-administration of NS 9283 (3.5 μmol/kg; i.p.; single dose) potentiates the reversal effect of ABT-594 (HY-14316A) on carrageenan-induced hyperalgesia in rats by 6-fold, whereas NS 9283 alone shows no analgesic activity even at a dose as high as 35 μmol/kg^[5].
Combination of NS 9283 (3.5 or 35 μmol/kg; p.o.) with 30 nmol/kg ABT-594 potentiates ABT-594-induced brain functional activity, producing approximately a 5-fold enhancement, whereas 35 μmol/kg NS 9283 alone does not significantly alter brain function signals^[5].
NS 9283 (intraperitoneal injection; single pre-treatment, dose 0.35-3.5 mg/kg) dose-dependently attenuates nicotine self-administration behavior in male Sprague Dawley rats under the FR5 schedule, while no such effect is observed at the dose of 0.35 mg/kg^[6].
NS 9283 (3.5 mg/kg; i.p.; single pretreatment) reduces the reinforcing effect of nicotine, as evidenced by decreases in breakpoints, active lever responses, and nicotine infusions in male Sprague Dawley rats under a progressive ratio (PR) schedule when nicotine is administered at doses of 0.03 mg/kg and 0.06 mg/kg^[6].
NS 9283 (0.35-3.5 mg/kg; i.p.; single pretreatment) dose-dependently attenuates cue- and nicotine-induced reinstatement of nicotine-seeking behavior in male Sprague Dawley rats, while no such effect is observed at the dose of 0.35 mg/kg^[6].
NS 9283 (administered via local pressure injection into the medial prefrontal cortex of rats at doses of 400-800 pmol) induces robust glutamate release in the rat medial prefrontal cortex (mPFC), and a dose-dependent increase in glutamate peak amplitude is observed in intact brain hemispheres^[1].
NS 9283 (400-800 pmol; local pressure ejection into mPFC) induces glutamate release in the medial prefrontal cortex (mPFC) of intact-side rats^[1].
NS 9283 (3 mg/kg; i.p.; single administration) enhances submaximal dose nicotine-induced glutamate release in the medial prefrontal cortex (mPFC) of rats by 48%^[1].